Results 161 to 170 of about 5,158 (194)
Some of the next articles are maybe not open access.
Journal of Inorganic and Nuclear Chemistry, 1965
Abstract The half-life of radium-223 has been determined simultaneously by microcalorimetry and proportional alpha counting, with 5 mc of radium-223 separated from actinium-227 and thorium-227 by cation exchange. A 4-mc fraction of the purified radium-223 was transferred to a tantalum capsule, dried, ignited at red heat, and hermetically sealed. The
H.W. Kirby +4 more
openaire +1 more source
Abstract The half-life of radium-223 has been determined simultaneously by microcalorimetry and proportional alpha counting, with 5 mc of radium-223 separated from actinium-227 and thorium-227 by cation exchange. A 4-mc fraction of the purified radium-223 was transferred to a tantalum capsule, dried, ignited at red heat, and hermetically sealed. The
H.W. Kirby +4 more
openaire +1 more source
Assessing therapeutic response to Radium-223
Seminars in Nuclear MedicineRadium-223 (223Ra), an alpha-emitting radiopharmaceutical targets bone and prolongs overall survival (OS) while reducing skeletal-related events (SREs) in metastatic castration-resistant prostate cancer patients (mCRPC). However, assessing 223Ra therapeutic response is difficult due to its distinct mechanism of action on bone remodeling and tumor ...
Caroline Torricelli +2 more
openaire +2 more sources
Info Onkologie, 2014
Fur Patienten mit metastasiertem kastrationsresistentem Prostatakrebs (mCRPC) ist Radium-223 eine interessante Option.
openaire +1 more source
Fur Patienten mit metastasiertem kastrationsresistentem Prostatakrebs (mCRPC) ist Radium-223 eine interessante Option.
openaire +1 more source